Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gabriel Steg

Showing results (941-950 of 962) with videos related to

Pageof 97
Sort By:
The New England Journal of Medicine|April 8, 2024
Apolipoprotein A1 Infusions and Cardiovascular Outcomes after Acute Myocardial InfarctionC Michael Gibson, Danielle Duffy, Serge Korjian, et al.
American Heart Journal|February 12, 2022
Causes of cardiovascular and noncardiovascular death in the ISCHEMIA trialMandeep S Sidhu, Karen P Alexander, Zhen Huang, et al.
The New England Journal of Medicine|April 8, 2024
Empagliflozin after Acute Myocardial InfarctionJaved Butler, W Schuyler Jones, Jacob A Udell, et al.
European Heart Journal|June 5, 2026
Predicting lifetime cardiovascular risk and benefits of preventive treatment in patients with established atherosclerotic cardiovascular disease: the SMART-REACH2 modelJoris Holtrop, Mari N Gynnild, Salil V Deo, et al.
Journal of the American College of Cardiology|April 8, 2024
Left Ventricular Function, Congestion, and Effect of Empagliflozin on Heart Failure Risk After Myocardial InfarctionJacob A Udell, Mark C Petrie, W Schuyler Jones, et al.
Circulation. Cardiovascular Interventions|December 17, 2024
Relationship Between Severity of Ischemia and Coronary Artery Disease for Different Stress Test Modalities in the ISCHEMIA TrialHarmony R Reynolds, Courtney B Page, Leslee J Shaw, et al.
Critical Care Explorations|November 13, 2023
Pharmacologic and Genetic Downregulation of Proprotein Convertase Subtilisin/Kexin Type 9 and Survival From SepsisPatrick R Lawler, Garen Manvelian, Alida Coppi, et al.
Circulation|April 6, 2024
Effect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights From the EMPACT-MI TrialAdrian F Hernandez, Jacob A Udell, W Schuyler Jones, et al.
Circulation|June 19, 2023
Defining Strategies of Modulation of Antiplatelet Therapy in Patients With Coronary Artery Disease: A Consensus Document from the Academic Research ConsortiumDavide Capodanno, Roxana Mehran, Mitchell W Krucoff, et al.
Journal of the American College of Cardiology|April 8, 2024
Effect of Reconstituted Human Apolipoprotein A-I on Recurrent Ischemic Events in Survivors of Acute MIThomas J Povsic, Serge Korjian, M Cecilia Bahit, et al.
Pageof 97

Showing results (941-950 of 962) with videos related to

Sort By:
Pageof 97
The New England Journal of Medicine|April 8, 2024
Apolipoprotein A1 Infusions and Cardiovascular Outcomes after Acute Myocardial InfarctionC Michael Gibson, Danielle Duffy, Serge Korjian, et al.
American Heart Journal|February 12, 2022
Causes of cardiovascular and noncardiovascular death in the ISCHEMIA trialMandeep S Sidhu, Karen P Alexander, Zhen Huang, et al.
The New England Journal of Medicine|April 8, 2024
Empagliflozin after Acute Myocardial InfarctionJaved Butler, W Schuyler Jones, Jacob A Udell, et al.
European Heart Journal|June 5, 2026
Predicting lifetime cardiovascular risk and benefits of preventive treatment in patients with established atherosclerotic cardiovascular disease: the SMART-REACH2 modelJoris Holtrop, Mari N Gynnild, Salil V Deo, et al.
Journal of the American College of Cardiology|April 8, 2024
Left Ventricular Function, Congestion, and Effect of Empagliflozin on Heart Failure Risk After Myocardial InfarctionJacob A Udell, Mark C Petrie, W Schuyler Jones, et al.
Circulation. Cardiovascular Interventions|December 17, 2024
Relationship Between Severity of Ischemia and Coronary Artery Disease for Different Stress Test Modalities in the ISCHEMIA TrialHarmony R Reynolds, Courtney B Page, Leslee J Shaw, et al.
Critical Care Explorations|November 13, 2023
Pharmacologic and Genetic Downregulation of Proprotein Convertase Subtilisin/Kexin Type 9 and Survival From SepsisPatrick R Lawler, Garen Manvelian, Alida Coppi, et al.
Circulation|April 6, 2024
Effect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights From the EMPACT-MI TrialAdrian F Hernandez, Jacob A Udell, W Schuyler Jones, et al.
Circulation|June 19, 2023
Defining Strategies of Modulation of Antiplatelet Therapy in Patients With Coronary Artery Disease: A Consensus Document from the Academic Research ConsortiumDavide Capodanno, Roxana Mehran, Mitchell W Krucoff, et al.
Journal of the American College of Cardiology|April 8, 2024
Effect of Reconstituted Human Apolipoprotein A-I on Recurrent Ischemic Events in Survivors of Acute MIThomas J Povsic, Serge Korjian, M Cecilia Bahit, et al.
Pageof 97